Cas:148989-73-5 7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid manufacturer & supplier

Chemical Name:7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid

CAS.NO:148989-73-5

Synonyms:7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid

Molecular Formula:C₂₂H₂₈O₄

Molecular Weight:356.45500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:77.76000

Exact Mass:356.19900

LogP:5.19000

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid Use and application,7-(2,5-dihydroxy-3,4,6-trimethylphenyl)-7-phenylheptanoic acid technical grade,usp/ep/jp grade.

Related News: One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. Dimethylsulfoxid-p-Hydroxytoluol-Addukt manufacturers Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. methyl 2′,3′,4′,5′,6′-pentafluoro-[1,1′-biphenyl]-4-carboxylate suppliers One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. 6-Amino-5-[(E)-4-chloro-phenylimino]-5H-quinolin-8-one vendor & factory Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. ,The government has approved a total of 33 applications with a committed investment of Rs 5,082.65 crore under the production linked incentive scheme for active pharmaceutical ingredients, an official release said on Thursday.